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Background
Turcot syndrome is clinically characterized by the
occurrence of primary brain tumors, colorectal cancer
and/or accompanying adenomas. It has been described
as both an autosomal dominant and recessive condition
and mutations in APC, MLH1, MSH2, MSH6 and
PMS2 have been reported. Constitutional Mismatch
repair (CMMR) deficiency is a variant of Lynch syn-
drome (LS) associated with biallelic MMR mutations.
Individuals present with NF1 manifestations and gener-
ally develop hematological malignancies, brain tumors
and/or LS associated cancers, in the first or second dec-
ade of life. We report an individual with café au lait
macules (CAL) and a history of glioblastoma at 31 and
proximal colon cancer at 32. Family history includes a
mother with hematologic cancers in her 60’s, maternal
half uncle with colon cancer at 48, maternal half uncle
with renal cancer and three maternal great uncles with
colon cancer.
Methods
The proband underwent a standard clinical assessment
in the cancer genetics clinic.
Immunohistochemistry (IHC) and genetic testing for
MLH1, MSH2, MSH6 and PMS2 was completed fol-
lowed by microsatellite (MSI) studies and imunohisto-
chemistry (IHC) for PMS2.
Results
IHC on tissue from the patient’s colorectal tumor
showed very weak staining of MLH1 in both the tumor
and benign colonic mucosa and lymphocytes. No muta-
tion was detected by sequencing and MLPA for MLH1,
MSH2 and MSH6. MSI was high and subsequent IHC
for PMS2 showed absent staining. Sequencing of PMS2
identified two changes: 2019 delT resulting in a frame-
shift mutation at codon 673 and 2249G>A (G750D), a
missense change in a fully conserved region. In-silico
analysis by SIFT [http://sift.jcvi.org/] and Polyphen
[http://genetics.bwh.harvard.edu/pph/] predict the mis-
sense change to be damaging. This change has also been
previously reported as a biallelic mutation in individual
with a complete PMS2 gene deletion and history of rec-
tal cancer and brain tumor at 22 and 23 respectively [1].
The proband’s mother is currently being tested to con-
firm the two PMS2 mutations are in trans.
Conclusions
We report an individual with Turcot syndrome and bial-
lelic PMS2 mutations who developed her first cancer in
her 30’s. In this case, biallelic mutations were suspected
due to the history of CALs. This result is in keeping
with recent reports suggesting a milder phenotype may
exist in individuals with biallelic PMS2 mutations, parti-
cularly in those where one mutation may be hypo-
morphic resulting in some residual MMR proficiency.
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